AstraZeneca(US:AZN) Sou Hu Cai Jing·2025-10-26 03:24Core Insights - AstraZeneca has officially launched its new Global Strategic R&D Center in Beijing, marking its sixth global and second in China, as part of a $2.5 billion (approximately 18 billion RMB) investment plan [1][3] - The Beijing center will leverage advanced artificial intelligence and data science to accelerate the transition of early drug research results into clinical development [1] - The center aims to enhance collaboration with local clinical trial institutions, universities, and biotech companies to deepen disease understanding and foster scientific innovation [1][3] Company Collaborations - AstraZeneca announced multiple collaborations to promote global cooperation and accelerate new drug development, including partnerships with the University of Cambridge, Beijing Municipal Science and Technology Commission, Zhongguancun Science Park Management Committee, and Beijing Economic-Technological Development Area Management Committee [3] - These collaborations will strengthen the connection between the leading scientific ecosystems of Beijing and Cambridge through shared educational resources, training, and talent exchange [3] - AstraZeneca has also initiated research collaboration with HAPO Pharmaceuticals in the fields of oncology and autoimmune diseases, with a new innovation laboratory established adjacent to the Beijing R&D center [3] Workforce Expansion - The series of initiatives will increase AstraZeneca's workforce in Beijing to approximately 1,700 employees, further solidifying its R&D presence in China and reinforcing Beijing's status as a key global life sciences hub [3]